Apeloa Pharmaceutical (000739) Fundamentals 2026 — P/E 26.7x, Revenue Analysis | SniperIQ
Apeloa Pharmaceutical (000739) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥24.1B, trading at ¥20.84 on the SHZ. This SniperIQ fundamentals page covers Apeloa Pharmaceutical's valuation (P/E 26.7x, P/B 3.6x), profitability (net margin 9.4%), revenue (¥9.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Apeloa Pharmaceutical's market cap?
Apeloa Pharmaceutical (000739) has a market capitalization of approximately ¥24.1B, trading at ¥20.84 on the SHZ. Market cap moves with the live share price.
What is Apeloa Pharmaceutical's P/E ratio?
Apeloa Pharmaceutical's trailing twelve-month P/E ratio is 26.7x, with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Apeloa Pharmaceutical?
Apeloa Pharmaceutical runs a net profit margin of 9.4%, a gross margin of 27.0%, and an operating margin of 10.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Apeloa Pharmaceutical generate?
Apeloa Pharmaceutical reported revenue of ¥9.8B for fiscal year 2025, with net income of ¥891M and earnings per share (EPS) of 0.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Apeloa Pharmaceutical pay a dividend?
Apeloa Pharmaceutical offers a trailing dividend yield of about 2.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Apeloa Pharmaceutical financially healthy?
Apeloa Pharmaceutical carries a debt-to-equity ratio of 0.45x and a current ratio of 1.55x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Apeloa Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Apeloa Pharmaceutical (000739) the key facts are: market cap ¥24.1B, P/E 26.7x, revenue ¥9.8B, 52-week range 14.89-21.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Apeloa Pharmaceutical's full fundamentals live
Get Apeloa Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.